var data={"title":"Nicotine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nicotine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6650?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nicotine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nicotine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201268\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GoodSense Nicotine [OTC];</li>\n      <li>Nicoderm CQ [OTC];</li>\n      <li>Nicorelief [OTC];</li>\n      <li>Nicorette Mini [OTC];</li>\n      <li>Nicorette Starter Kit [OTC];</li>\n      <li>Nicorette [OTC];</li>\n      <li>Nicotine Step 1 [OTC];</li>\n      <li>Nicotine Step 2 [OTC];</li>\n      <li>Nicotine Step 3 [OTC];</li>\n      <li>Nicotrol;</li>\n      <li>Nicotrol NS;</li>\n      <li>Thrive [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201269\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Habitrol;</li>\n      <li>Nicoderm;</li>\n      <li>Nicorette;</li>\n      <li>Nicorette Plus;</li>\n      <li>Nicotrol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201309\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Smoking Cessation Aid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201272\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Smoking cessation (patients should completely stop smoking upon initiation of therapy):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gum:</i> Chew 1 piece of gum when urge to smoke occurs. If strong or frequent cravings are present after 1 piece of gum, may use a second piece within the hour (do not continuously use one piece after the other). Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1 to 6: Chew 1 piece of gum every 1 to 2 hours (maximum: 24 pieces/day); to increase chances of quitting, chew at least 9 pieces/day during the first 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 7 to 9: Chew 1 piece of gum every 2 to 4 hours (maximum: 24 pieces/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 10 to 12: Chew 1 piece of gum every 4 to 8 hours (maximum: 24 pieces/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalation:</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial treatment</i>: 6 to 16 cartridges/day (at least 6 cartridges/day for the first 3 to 6 weeks) for up to 12 weeks; maximum: 16 cartridges/day. <b>Note:</b> Best effect achieved with frequent continuous puffing (20 minutes). Use beyond 6 months is not recommended (has not been studied). If patient is unable to stop smoking by the fourth week of therapy, consider discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Discontinuation of therapy:</i> After initial treatment, gradually reduce daily dose over 6 to 12 weeks. Some patients may not require gradual reduction of dosage and may stop treatment abruptly. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lozenge:</i> Oral: 1 lozenge when urge to smoke occurs; do not use more than 1 lozenge at a time. Patients who smoke their first cigarette within 30 minutes of waking should use the 4 mg strength; otherwise the 2 mg strength is recommended. Use according to the following 12-week dosing schedule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 1 to 6: 1 lozenge every 1 to 2 hours (maximum: 5 lozenges every 6 hours; 20 lozenges/day); to increase chances of quitting, use at least 9 lozenges/day during the first 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 7 to 9: 1 lozenge every 2 to 4 hours (maximum: 5 lozenges every 6 hours; 20 lozenges/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weeks 10 to 12: 1 lozenge every 4 to 8 hours (maximum: 5 lozenges every 6 hours; 20 lozenges/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Nasal:</i> Spray: Initial: 1 to 2 doses/hour (each dose [2 sprays, one in each nostril] contains 1 mg of nicotine); adjust dose as needed based on patient response; do not exceed more than 5 doses (10 sprays) per hour [maximum: 40 mg/day (80 sprays)] or 3 months of treatment. <b>Note:</b> For best results, use at least the recommended minimum of 8 doses per day (less is unlikely to be effective). Use beyond 6 months is not recommended (has not been studied). If patient is unable to stop smoking by the fourth week of therapy, consider discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Discontinuation of therapy:</i> Discontinue over 4 to 6 weeks. Some patients may not require gradual reduction of dosage and may stop treatment abruptly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Transdermal patch:</i> Topical: <b>Note:</b> Adjustment may be required during initial treatment (move to higher dose if experiencing withdrawal symptoms; lower dose if side effects are experienced).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients smoking &gt;10 cigarettes/day: Begin with step 1 (21 mg/day) for 6 weeks, <b>followed by</b> step 2 (14 mg/day) for 2 weeks; <b>finish with</b> step 3 (7 mg/day) for 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients smoking &le;10 cigarettes/day: Begin with step 2 (14 mg/day) for 6 weeks, <b>followed by</b> step 3 (7 mg/day) for 2 weeks</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201273\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44661366\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Only severe renal impairment should affect clearance of nicotine or its metabolites from circulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44661367\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); because total system clearance of nicotine is dependent on hepatic blood flow, anticipate reduced clearance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201244\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gum, Mouth/Throat, as polacrilex: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorelief: 2 mg (50 ea, 110 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorelief: 2 mg (50 ea, 110 ea) [mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorelief: 4 mg (50 ea, 110 ea) [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorelief: 4 mg (50 ea, 110 ea) [contains fd&amp;c yellow #10 (quinoline yellow); mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (170 ea, 200 ea) [original flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (40 ea [DSC]) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (190 ea) [contains menthol; fresh mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (20 ea, 100 ea, 160 ea, 190 ea) [contains menthol; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (110 ea, 170 ea) [contains menthol; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (20 ea, 100 ea, 160 ea, 190 ea) [contains menthol, polysorbate 80; cinnamon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (20 ea, 100 ea, 160 ea, 190 ea [DSC]) [contains menthol, polysorbate 80; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (100 ea, 160 ea) [contains menthol, polysorbate 80; spearmint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (170 ea, 200 ea) [contains fd&amp;c yellow #10 (quinoline yellow); original flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (100 ea, 160 ea, 190 ea [DSC]) [contains fd&amp;c yellow #10 (quinoline yellow), menthol, polysorbate 80; cinnamon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (40 ea [DSC]) [contains fd&amp;c yellow #10 aluminum lake, menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (100 ea, 190 ea) [contains fd&amp;c yellow #10 aluminum lake, menthol; fresh mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (20 ea, 100 ea, 160 ea, 190 ea) [contains fd&amp;c yellow #10 aluminum lake, menthol; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (110 ea, 170 ea) [contains fd&amp;c yellow #10 aluminum lake, menthol; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (160 ea) [contains fd&amp;c yellow #10 aluminum lake, menthol, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (20 ea, 100 ea, 160 ea, 190 ea) [contains fd&amp;c yellow #10 aluminum lake, menthol, polysorbate 80; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette Starter Kit: 2 mg (110 ea) [original flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette Starter Kit: 2 mg (100 ea) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette Starter Kit: 4 mg (110 ea) [contains fd&amp;c yellow #10 aluminum lake; original flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Thrive: 2 mg (100 ea, 110 ea [DSC]) [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg (20 ea, 40 ea, 50 ea, 100 ea, 110 ea); 4 mg (20 ea, 40 ea, 50 ea, 100 ea, 110 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Inhaler, Inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicotrol: 10 mg (168 ea) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 7 mg/24 hr (14s) &amp; 14 mg/24 hr (14s) &amp; 21 mg/24 hr (28s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lozenge, Mouth/Throat, as polacrilex: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Nicotine: 4 mg (72 ea) [contains aspartame; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoodSense Nicotine: 2 mg (27 ea); 4 mg (27 ea) [gluten free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (81 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (72 ea) [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (108 ea) [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (81 ea [DSC]) [contains aspartame, soy protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 2 mg (24 ea, 27 ea, 72 ea, 168 ea) [contains aspartame, soy protein; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (72 ea, 81 ea [DSC]) [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (108 ea) [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (81 ea [DSC]) [contains aspartame, soy protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette: 4 mg (24 ea, 72 ea, 168 ea) [contains aspartame, soy protein; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette Mini: 2 mg (20 ea, 81 ea, 135 ea); 4 mg (20 ea, 81 ea, 135 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg (24 ea, 27 ea, 72 ea [DSC]); 4 mg (24 ea, 27 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch 24 Hour, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicoderm CQ: 7 mg/24 hr (14 ea); 14 mg/24 hr (14 ea, 21 ea); 21 mg/24 hr (7 ea, 14 ea, 21 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicotine Step 3: 7 mg/24 hr (14 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicotine Step 2: 14 mg/24 hr (14 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicotine Step 1: 21 mg/24 hr (14 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 7 mg/24 hr (1 ea, 7 ea, 14 ea); 14 mg/24 hr (1 ea [DSC], 7 ea, 14 ea); 21 mg/24 hr (1 ea [DSC], 7 ea, 14 ea, 28 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicotrol NS: 10 mg/mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201229\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46518813\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Nicotrol NS contains approximately 200 sprays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201248\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gum: Chew slowly until it tingles, then place gum between cheek and gum until tingle is gone; repeat process until most of tingle is gone (~30 minutes). Do not eat or drink 15 minutes before using or while the gum is in mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lozenge: Do not chew or swallow; allow to dissolve slowly (~20 to 30 minutes); minimize swallowing and occasionally move lozenge from one side of the mouth to the other until completely dissolved. Do not eat or drink 15 minutes before using or while lozenge is in mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasal spray: Prime pump prior to first use (pump 6 to 8 times until fine spray appears) or if it has not been used for 24 hours (pump 1 to 2 times); avoid excessive priming. Blow nose prior to use. Tilt head back slightly and insert tip of bottle into nostril. Breathe through mouth and spray once in each nostril. Do not sniff, swallow, or inhale through the nose during administration. After administration, wait 2 to 3 minutes before blowing nose. Avoid contact with skin, eyes, and mouth (nicotine overdose can occur when nicotine is absorbed through the skin).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral Inhalation: Insert cartridge into inhaler and push hard until it pops into place. Replace mouthpiece and twist the top and bottom so that markings do not line up. Inhale deeply into the back of the throat or puff in short breaths. Nicotine in cartridge is used up after about 20 minutes of active puffing. Clean mouthpiece regularly with soap and water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal patch: Apply new patch to nonhairy, clean, dry skin on the upper body or upper outer arm; each patch should be applied to a different site. Apply immediately after removing backing from patch; press onto skin for ~10 seconds. Patch may be worn for 16 or 24 hours. If cigarette cravings occur upon awakening, wear for 24 hours; if vivid dreams or other sleep disturbances occur, remove the patch at bedtime and apply a new patch in the morning. Do not cut patch; causes rapid evaporation, rendering the patch useless. Do not wear more than 1 patch at a time; do not leave patch on for more than 24 hours (may irritate skin). Wash hands after applying or removing patch. Discard patches by folding adhesive ends together, replace in pouch and dispose of properly in trash.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132652\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent; use appropriate precautions for handling and disposal (EPA, P-listed).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201247\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Smoking cessation:</b> Treatment to aid smoking cessation for the relief of nicotine withdrawal symptoms (including nicotine craving)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201316\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NicoDerm may be confused with Nitroderm </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nicorette may be confused with Nordette</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201236\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal spray/inhaler:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Headache (18% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Inhaler: Mouth irritation (&le;66%), dyspepsia (18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Inhaler: Throat irritation (&le;66%), cough (32%), rhinitis (23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Central nervous system: Withdrawal syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic: Acne vulgaris (3%), burning sensation of the nose (nasal spray)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gastrointestinal: Flatulence (4%), gingival disease (4%), diarrhea, dysgeusia, hiccups, nausea, tooth enamel damage (abrasions)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genitourinary: Dysmenorrhea (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuromuscular &amp; skeletal: Back pain (6%), arthralgia (5%), jaw pain, neck pain</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Respiratory: Sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1%, postmarketing, and/or case reports: Amnesia, aphasia, bronchitis, bronchospasm, edema, hypersensitivity reaction, increased bronchial secretions, migraine, numbness, pain, purpura, skin rash, visual disturbance, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adverse events reported for chewing gum, lozenge, and/or transdermal systems were reported in prescription labeling. Frequency not defined; may be product- or dose-specific:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression, dizziness, headache, insomnia, lack of concentration, nervousness, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Aphthous stomatitis, constipation, diarrhea, dysgeusia, dyspepsia, flatulence, gingival hemorrhage, glossitis, hiccups, nausea, sialorrhea, stomatitis, tooth enamel damage (abrasions), xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Application site reaction, localized edema, localized erythema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, jaw pain, myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, sinusitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201251\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to nicotine or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: Nicorette lozenge: When used for self-medication, do not use if you are allergic to soya.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201233\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Nicotine can increase heart rate and blood pressure. The risk versus the benefits should be weighed in patients with cardiovascular or peripheral vascular diseases, specifically patients with a history of myocardial infarction and/or angina pectoris, serious cardiac arrhythmias, or vasospastic diseases (Buerger disease, Prinzmetal variant angina, Raynaud phenomena); use caution in patients with angina, hypertension, or recent MI. Discontinue use if irregular heartbeat or palpitations occur. Use caution in patients with accelerated hypertension due to the risk of malignant hypertension. Generally, avoid use during the immediate postmyocardial infarction period, in patients with serious arrhythmias, or with severe or worsening angina.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with insulin-dependent diabetes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with active peptic ulcer disease; healing may be delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; effects on metabolism unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pheochromocytoma: Use with caution in patients with pheochromocytoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with severe renal impairment; effects on elimination unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chewing gum: OTC labeling: When used for self-medication, consult a health care provider before use in patients on a sodium-restricted diet and in patients with a history of seizures. Discontinue use and consult a health care provider if mouth, teeth, or jaw problems occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inhaler: Use with caution in patients with bronchospastic disease (eg, asthma, chronic pulmonary disease); may cause bronchospasm due to potential airway irritation; other forms of nicotine replacement may be preferred in patients with severe bronchospastic airway disease. Sustained use (beyond 6 months) by patients who quit smoking is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lozenge: OTC labeling: When used for self-medication, consult a health care provider before use in patients on a sodium-restricted diet and in patients with a history of seizures. Discontinue use and consult a health care provider if mouth problems, persistent indigestion, or severe sore throat occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nasal spray: Use of nasal product is not recommended with chronic nasal disorders (eg, allergy, rhinitis, nasal polyps, and sinusitis). Exacerbations of bronchospasm have been reported in patients with preexisting asthma; use in patients with severe reactive airway disease is not recommended. Nasal mucosa irritation may occur. Sustained use (beyond 6 months) by patients who quit smoking is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI. OTC labeling: When used for self-medication, consult a health care provider before use in patients who have an allergy to adhesive tape or who have skin problems. Discontinue use and contact a health care provider if skin redness caused by the patch does not resolve after 4 days or if inflammation or rash occurs. If vivid dreams or other sleep disturbances occur, remove the patch at bedtime and apply another patch in the morning.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Urge patients to stop smoking completely when initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: When used for self-medication, discontinue use and contact a health care provider if symptoms of nicotine overdose (eg, nausea, vomiting, dizziness, diarrhea, weakness, rapid heartbeat) or an allergic reaction (eg, difficulty breathing, rash) occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201303\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201238\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9698&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Nicotine may enhance the AV-blocking effect of Adenosine. Nicotine may enhance the tachycardic effect of Adenosine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Nicotine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varenicline: May enhance the adverse/toxic effect of Nicotine.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201265\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Lozenge: Acidic foods/beverages decrease absorption of nicotine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2725078\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Nicotine crosses the placenta (HHS 2014). Maternal smoking is associated with birth defects (HHS 2014; Hachshaw 2011); the incidence of birth defects following nicotine replacement therapy may be similar (limited data) (Dhalwani 2015). Nicotine exposure via cigarette smoke may cause increased ectopic pregnancy, low birth weight, increased risk of spontaneous abortion, increased perinatal mortality; increased aortic blood flow, increased heart rate, decreased uterine blood flow, and decreased breathing have been reported in the fetus. Smoking during pregnancy is associated with sudden infant death syndrome (SIDS), an increased risk of asthma, infantile colic, and childhood obesity (ACOG 2010; HHS 2014). Women who are pregnant should be encouraged not to smoke. The use of nicotine replacement products to aid in smoking cessation has not been adequately studied in pregnant women (amount of nicotine exposure is varied). Nonpharmacologic treatments are recommended. If the benefits of nicotine replacement therapy outweigh the unknown risks, it should be done under close supervision (ACOG 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2725080\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Nicotine from cigarette smoke is present in breast milk and can be absorbed orally by the infant; hepatic clearance is likely lowest at birth. The amount of nicotine in breast milk from replacement products varies. Nicotine replacement therapy is considered to be compatible with breastfeeding if the amount of nicotine is less than that received from smoking. Use of short acting products (gum, lozenges) is preferred (Sachs 2013). The manufacturer recommends that caution be exercised when administering nicotine to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201255\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Some products may contain phenylalanine and/or sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201242\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of nicotine toxicity (eg, severe headache, dizziness, mental confusion, disturbed hearing and vision, abdominal pain; rapid, weak and irregular pulse; salivation, nausea, vomiting, diarrhea, cold sweat, weakness)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201232\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Nicotine, a naturally occurring alkaloid, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of CNS effects are believed to be the basis of nicotine's positively reinforcing properties; a stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201250\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Intranasal: More closely approximate the time course of plasma nicotine levels observed after cigarette smoking than other dosage forms (Svensson 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Buccal mucosa, transdermal: Slow; Intranasal: ~53%; Inhaler: &lt;5% reaches the lower respiratory tract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 2 to 3 L/kg (Svensson 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 5% to 20% (Svensson 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (major), kidney, and lung; &gt;20 metabolites (primary metabolites are cotinine and trans-3-hydroxycotinine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Transdermal: ~4 hours (Bannon 1989); Intranasal: 1 to 2 hours; Oral inhalation: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Transdermal: ~2 to 8 hours (Bannon 1989; DeVeaugh-Geiss 2010); Intranasal: 4 to 15 minutes; Oral inhalation: &le;15 minutes; Gum: ~30 minutes (Svensson 1987)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~10% as unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201254\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gum</b> (Nicorelief Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (50): $29.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (50): $29.49</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gum</b> (Nicorette Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (20): $8.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $50.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gum</b> (Nicorette Starter Kit Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $50.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (110): $50.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gum</b> (Nicotine Polacrilex Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $39.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (100): $41.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gum</b> (Thrive Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (100): $42.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Inhalation</b> (Nicotrol Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (168): $499.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Nicotine Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21-14-7 mg/24 hrs (56): $102.35</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (Nicorette Mini Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (81): $43.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (20): $10.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (Nicorette Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (24): $10.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (24): $10.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lozenge</b> (Nicotine Polacrilex Mouth/Throat)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg (24): $11.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (27): $12.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Nicoderm CQ Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7 mg/24 hrs (14): $23.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">14 mg/24 hrs (14): $23.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21 mg/24 hrs (14): $50.46</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch, 24-hour</b> (Nicotine Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7 mg/24 hrs (7): $16.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">14 mg/24 hrs (7): $16.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">21 mg/24 hrs (14): $29.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Nicotrol NS Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (10 mL): $131.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201256\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>EKMO (MT);</li>\n      <li>Habitrol Gum (NZ);</li>\n      <li>Nicabate (AU);</li>\n      <li>Nicabate Clear (AU);</li>\n      <li>Nicabate CQ (NZ);</li>\n      <li>Nicabate Lozenges (AU);</li>\n      <li>Nicabate Soft Gum (AU);</li>\n      <li>Nicolan TTS (AE);</li>\n      <li>Nicoman (KR);</li>\n      <li>Nicomild (TH);</li>\n      <li>Nicopass sans sucre menthe fraicheur (FR);</li>\n      <li>Nicopass sans sucre reghsse menthe (FR);</li>\n      <li>Nicopatch (FR);</li>\n      <li>Nicorest (FR);</li>\n      <li>Nicorette (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BR, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, HR, HU, IE, IL, IQ, IR, IS, IT, JO, JP, KE, KW, LB, LR, LT, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PL, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SV, SY, TN, TW, TZ, UG, VE, YE, ZA, ZM, ZW);</li>\n      <li>Nicorette Coolmint (TH);</li>\n      <li>Nicorette Fruit (FR);</li>\n      <li>Nicorette Inhaler (AU);</li>\n      <li>Nicorette Menthe (AE, BH, CY, EG, FR, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Nicorette Menthe Fraiche (FR);</li>\n      <li>Nicorette Orange (FR);</li>\n      <li>Nicorette Orange sans sucre (FR);</li>\n      <li>Nicostop (PT);</li>\n      <li>Nicotab (SE);</li>\n      <li>Nicotinell (AE, AT, AU, BE, BG, BH, CH, DE, DK, FI, FR, GB, GR, IE, IS, IT, KW, LT, LV, NL, NO, PL, PT, SA, SE, SI, TR);</li>\n      <li>Nicotinell Chewing Gum (HK);</li>\n      <li>Nicotinell Fruit sans sucre (FR);</li>\n      <li>Nicotinell Menthe sans sucre (FR);</li>\n      <li>Nicotinell Mint Lozenge (KR);</li>\n      <li>Nicotinell TTS (AE, AR, BF, BH, BJ, BM, BS, BZ, CI, CL, CY, EE, EG, ET, FR, GH, GM, GN, GY, HK, HR, HU, IL, IQ, IR, JM, JO, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NZ, OM, PH, PR, QA, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, UY, YE, ZM, ZW);</li>\n      <li>Nicotrans (IT);</li>\n      <li>Nicotrol Gum (NZ);</li>\n      <li>Nikofrenon (DE);</li>\n      <li>Nikorette (UA);</li>\n      <li>Nikotynell (UA);</li>\n      <li>Nikvityn (UA);</li>\n      <li>Niquitin (BR, CO, JO, KW, MT, MX, QA, SA);</li>\n      <li>NiQuitin (IE);</li>\n      <li>Niquitin Clear (HR, RO);</li>\n      <li>Niquitin CQ (HR, IL, SG);</li>\n      <li>Niquitin CQ Clear (IL);</li>\n      <li>Niquitin Mint (TW);</li>\n      <li>Niquitin sans sucre (FR);</li>\n      <li>Nobacco (LK);</li>\n      <li>Nosmok (LK, PH);</li>\n      <li>Pelzont (RO);</li>\n      <li>QuitX (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee Opinion, Committee opinion no. 471: Smoking cessation during pregnancy. <i>Obstet Gynecol</i>. 2010 Nov;116(5):1241-1244. doi: 10.1097/AOG.0b013e3182004fcd.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/20966731/pubmed\" target=\"_blank\" id=\"20966731\">20966731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bannon YB, Corish J, Corrigan OI, Devane JG, Kavanagh M, Mulligan S. Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. <i>Eur J Clin Pharmacol</i>. 1989;37(3):285-290.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/2612544/pubmed\" target=\"_blank\" id=\"2612544\">2612544</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benowitz NL, &ldquo;Pharmacologic Aspects of Cigarette Smoking and Nicotine Addiction,&rdquo; <i>N Engl J Med</i>, 1988, 319(20):1318-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/3054551/pubmed\" target=\"_blank\" id=\"3054551\">3054551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benowitz NL, Jacob P 3rd, and Sachs DP, &ldquo;Deficient C-oxidation of Nicotine,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57(5):590-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/7768082/pubmed\" target=\"_blank\" id=\"7768082\">7768082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blanchard J, &ldquo;Nicotine,&rdquo; <i>Clin Toxicol Rev</i>, 1993, 15:11-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies GM, Willner P, James DL, et al, &ldquo;Influence of Nicotine Gum on Acute Cravings for Cigarettes,&rdquo; <i>J Psychopharmacol</i>, 2004, 18(1):83-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/15107189 /pubmed\" target=\"_blank\" id=\"15107189 \">15107189 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeVeaugh-Geiss AM, Chen LH, Kotler ML, Ramsay LR, Durcan MJ. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. <i>Clin Ther</i>. 2010;32(6):1140-1148.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/20637967/pubmed\" target=\"_blank\" id=\"20637967\">20637967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dhalwani NN, Szatkowski L, Coleman T, et al. Nicotine replacement therapy in pregnancy and major congenital anomalies in offspring. <i>Pediatrics</i>. 2015 May;135(5):859-867. doi: 10.1542/peds.2014-2560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/25847803/pubmed\" target=\"_blank\" id=\"25847803\">25847803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guslandi M, &ldquo;Long-Term Effects of a Single Course of Nicotine Treatment in Acute Ulcerative Colitis: Remission Maintenance in a 12-month Follow-up Study,&rdquo; <i>Int J Colorectal Dis</i>, 1999, 14(4-5):261-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/10647637/pubmed\" target=\"_blank\" id=\"10647637\">10647637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackshaw A, Rodeck C, Boniface S. Maternal smoking in pregnancy and birth defects: a systematic review based on 173 687 malformed cases and 11.7 million controls. <i>Hum Reprod Update</i>. 2011 Sep-Oct;17(5):589-604. doi: 10.1093/humupd/dmr022.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/21747128/pubmed\" target=\"_blank\" id=\"21747128\">21747128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harchelroad F, Potts K, Burdick J, et al, &ldquo;Oral Absorption of Nicotine From Transdermal Therapeutic Systems,&rdquo; <i>Vet Hum Toxicol</i>, 1992, 34:332.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Healthcare Environmental Resource Center (HERC). Pharmaceuticals&mdash;Hazardous Waste. http://www.hercenter.org/hazmat/pharma.cfm#listed. Published 2015. Accessed October 23, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li Wan Po A, &ldquo;Transdermal Nicotine in Smoking Cessation. A Meta-Analysis,&rdquo; <i>Eur J Clin Pharmacol</i>, 1993, 45(6):519-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/8157037/pubmed\" target=\"_blank\" id=\"8157037\">8157037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGee D, Brabson T, McCarthy J, et al, &ldquo;Four-Year Review of Cigarette Ingestions in Children,&rdquo; <i>Pediatr Emerg Care</i>, 1995, 11(1):13-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/7739954/pubmed\" target=\"_blank\" id=\"7739954\">7739954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NicoDerm CQ (nicotine) transdermal system [prescribing information]. Moon Township, PA: GlaxoSmithKline Consumer Healthcare; received October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicorelief (nicotine) gum [prescribing information]. Livonia, MI: Major; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicorette (nicotine) gum [prescribing information]. Moon Township, PA: GlaxoSmithKline Consumer Healthcare; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicorette (nicotine) lozenge [prescribing information]. Moon Township, PA: GlaxoSmithKline Consumer Healthcare; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicorette Mini (nicotine) lozenge [prescribing information]. Moon Township, PA: GlaxoSmithKline Consumer Healthcare; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nicotrol (nicotine) inhalation system [prescribing information]. New York, NY: Pfizer; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nictotrol NS (nicotine) nasal spray [prescribing information]. New York, NY: Pfizer; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottervanger JP, Festen JM, de Vries AG, et al, &ldquo;Acute Myocardial Infarction While Using The Nicotine,&rdquo; <i>Chest</i>, 1995, 107(6):1765-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/7781384/pubmed\" target=\"_blank\" id=\"7781384\">7781384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pattishall EN, Strope GL, Etzel RA, et al, &ldquo;Serum Cotinine as a Measure of Tobacco Smoke Exposure in Children,&rdquo; <i>Am J Dis Child</i>, 1985, 139(11):1101-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/4061405/pubmed\" target=\"_blank\" id=\"4061405\">4061405</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross MP, Revolinski D, and Taurman L, &ldquo;Green Tobacco Sickness Among Adults in Kentucky,&rdquo; <i>Vet Hum Toxicol</i>, 1994, 36:360.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013 Sep;132(3):e796-809. doi: 10.1542/peds.2013-1985.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, &ldquo;Nicotine Therapy for Ulcerative Colitis: A Review of Rationale, Mechanisms, Pharmacology, and Clinical Results,&rdquo; <i>Am J Gastroenterol</i>, 1999, 94(5):1161-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/10235187/pubmed\" target=\"_blank\" id=\"10235187\">10235187</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, Tremaine WJ, Offord KP, et al, &ldquo;Transdermal Nicotine for Mildly to Moderately Active Ulcerative Colitis. A Randomized, Double-blind, Placebo-Controlled Trial,&rdquo; <i>Ann Intern Med</i>, 1997, 126(5):364-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/9054280/pubmed\" target=\"_blank\" id=\"9054280\">9054280</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smolinske SC, Spoerke DG, Spiller SK, et al, &ldquo;Cigarette and Nicotine Chewing Gum Toxicity in Children,&rdquo; <i>Hum Toxicol</i>, 1988, 7(1):27-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/3346035/pubmed\" target=\"_blank\" id=\"3346035\">3346035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Svensson CK, &ldquo;Clinical Pharmacokinetics of Nicotine,&rdquo; <i>Clin Pharmacokinet</i>, 1987, 12(1):30-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/3545615/pubmed\" target=\"_blank\" id=\"3545615\">3545615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas GA, Rhodes J, Mani V, et al, &ldquo;Transdermal Nicotine as Maintenance Therapy for Ulcerative Colitis,&rdquo; <i>N Engl J Med</i>, 1995, 332(15):988-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/7885427/pubmed\" target=\"_blank\" id=\"7885427\">7885427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Transdermal Nicotine Study Group, &ldquo;Transdermal Nicotine for Smoking Cessation. Six-month Results from Two Multicenter Controlled Clinical Trials,&rdquo; <i>JAMA</i>, 1991, 266(22):3133-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/1956099/pubmed\" target=\"_blank\" id=\"1956099\">1956099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Department of Health and Human Services (HHS). The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014 <a href=\"http://www.cdc.gov/tobacco/data_statistics/sgr/\" target=\"_blank\">http://www.cdc.gov/tobacco/data_statistics/sgr/</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Westman EC, Levin ED, and Rose JE, &ldquo;The Nicotine Patch in Smoking Cessation,&rdquo; <i>Arch Intern Med</i>, 1993, 153(16):1917-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nicotine-drug-information/abstract-text/8250653/pubmed\" target=\"_blank\" id=\"8250653\">8250653</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9698 Version 233.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201268\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F201269\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201309\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F201272\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F201273\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F44661366\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F44661367\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201244\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201229\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46518813\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F201248\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132652\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201247\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F201316\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201236\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201251\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201233\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F201303\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201238\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F201265\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2725078\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2725080\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F201255\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F201242\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201232\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201250\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F201254\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201256\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9698|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nicotine-patient-drug-information\" class=\"drug drug_patient\">Nicotine: Patient drug information</a></li></ul></div></div>","javascript":null}